Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP reduced its stake in Gossamer Bio by 19.3%, selling 166,860 shares during the first quarter, while still holding about 0.31% of the company worth approximately $765,000.
• Gossamer Bio reported $9.89 million in revenue for the last quarter, significantly exceeding the consensus estimate of $3.95 million, although it posted a loss of ($0.16) earnings per share.
• Analysts are optimistic about Gossamer Bio, with Wedbush issuing an "outperform" rating and a price target of $4.00, while Scotiabank set an even higher target of $11.00 for the stock.

GSA Capital Partners LLP cut its holdings in Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 19.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 695,553 shares of the company's stock after selling 166,860 shares during the quarter. GSA Capital Partners LLP owned about 0.31% of Gossamer Bio worth $765,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Mackenzie Financial Corp raised its position in Gossamer Bio by 17.6% in the first quarter. Mackenzie Financial Corp now owns 352,473 shares of the company's stock worth $388,000 after acquiring an additional 52,658 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in Gossamer Bio in the fourth quarter worth about $90,000. Velan Capital Investment Management LP bought a new stake in Gossamer Bio in the fourth quarter worth about $68,000. Two Sigma Investments LP raised its position in Gossamer Bio by 41.3% in the fourth quarter. Two Sigma Investments LP now owns 891,279 shares of the company's stock worth $806,000 after acquiring an additional 260,318 shares in the last quarter. Finally, Two Sigma Advisers LP raised its position in Gossamer Bio by 44.7% in the fourth quarter. Two Sigma Advisers LP now owns 1,157,500 shares of the company's stock worth $1,047,000 after acquiring an additional 357,500 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Price Performance

NASDAQ GOSS opened at $2.00 on Friday. The stock's 50-day moving average price is $1.41 and its two-hundred day moving average price is $1.20. The company has a current ratio of 5.71, a quick ratio of 5.71 and a debt-to-equity ratio of 6.70. The company has a market cap of $454.60 million, a PE ratio of -8.70 and a beta of 1.95. Gossamer Bio, Inc. has a 1 year low of $0.66 and a 1 year high of $2.18.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. Gossamer Bio had a negative return on equity of 128.98% and a negative net margin of 41.12%. On average, analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wedbush reiterated an "outperform" rating and issued a $4.00 price target on shares of Gossamer Bio in a research report on Friday, May 16th. Scotiabank began coverage on Gossamer Bio in a report on Monday, July 14th. They set a "sector outperform" rating and a $11.00 price objective on the stock. Finally, The Goldman Sachs Group boosted their price objective on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, May 16th.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.